Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neuraxis, INC
Report date July 01, 2025 · Filed July 03, 2025
Section 16 reporting ended · disclosed 2025-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-07-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-07-01 · Sale · Disposed 531,548 · Balance 0 Row 2 · 2025-07-01 · Conversion · Acquired 289,779 · Balance 289,779 Row 3 · 2025-07-01 · Sale · Disposed 289,779 · Balance 0 |
| Pre-Funded Warrant, Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-01 · Exercise / conversion · Disposed 289,779 · Balance 0 F1: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2025 Filed Jul 3, 2025 21:38 UTC | Neuraxis, INC NRXS · Entity 6994 | Exercise / conversionPre-Funded Warrant, Common Stock (Right to Buy) · Derivative | 289,779 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · derivative · entry 4 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 289,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock. F1 · derivative.expiration_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:38 UTC | Neuraxis, INC NRXS · Entity 6994 | SaleCommon Stock | 289,779 | $2.25 | $652,002.75 |
DisclosureSEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · nonDerivative · entry 3 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:38 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionCommon Stock | 289,779 | $0.00 | $28.98 |
DisclosureSEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · nonDerivative · entry 2 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:38 UTC | Neuraxis, INC NRXS · Entity 6994 | SaleCommon Stock | 531,548 | $2.25 | $1,195,983.00 |
DisclosureSEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · nonDerivative · entry 1 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:42 UTC Amendment | Neuraxis, INC NRXS · Entity 6994 | ConversionPre-Funded Warrant, Common Stock (Right to Buy) · Derivative | 289,779 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000937556-23-000202 · wf-form4a_169179734438990.xml · derivative · entry 4 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,779 Underlying: Common Stock · 289,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. F2 · derivative.expiration_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:42 UTC Amendment | Neuraxis, INC NRXS · Entity 6994 | ConversionPre-Funded Warrant, Series A Preferred Stock (Right to Buy) · Derivative | 144,890 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000937556-23-000202 · wf-form4a_169179734438990.xml · derivative · entry 3 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Series A Preferred Stock · 144,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. F2 · derivative.expiration_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. F2 · derivative.underlying_shares: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:42 UTC Amendment | Neuraxis, INC NRXS · Entity 6994 | ConversionSeries A Preferred Stock · Derivative | 265,774 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-23-000202 · wf-form4a_169179734438990.xml · derivative · entry 2 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 531,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:42 UTC Amendment | Neuraxis, INC NRXS · Entity 6994 | ConversionCommon Stock | 531,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000937556-23-000202 · wf-form4a_169179734438990.xml · nonDerivative · entry 1 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 21:16 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionPre-Funded Warrant, Common Stock (Right to Buy) · Derivative | 289,779 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000937556-23-000199 · wf-form4_169170219111216.xml · derivative · entry 4 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,779 Underlying: Common Stock · 289,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. F2 · derivative.expiration_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 21:16 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionPre-Funded Warrant, Series A Preferred Stock (Right to Buy) · Derivative | 144,890 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000937556-23-000199 · wf-form4_169170219111216.xml · derivative · entry 3 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Series A Preferred Stock · 144,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. F2 · derivative.expiration_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. F2 · derivative.underlying_shares: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.00005 per share of the Issuer's Common Stock. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 21:16 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionSeries A Preferred Stock · Derivative | 265,774 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-23-000199 · wf-form4_169170219111216.xml · derivative · entry 2 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 531,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 21:16 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionCommon Stock | 531,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000937556-23-000199 · wf-form4_169170219111216.xml · nonDerivative · entry 1 MASIMO CORP · CIK 0000937556 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each one share of Series A Preferred Stock converted automatically upon the Issuer's consummation of an initial public offering into two shares of the Issuer's Common Stock. The Series A Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.